Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | DPP4 | P27487 | 2/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | SCN4A | P35499 | 2/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1952916 | 1.00 | TAAR1 (0.62) | TAAR1HTR2ADPP4F2SCN4A | |
| SCHEMBL507194 | 1.00 | TAAR1 (0.62) | TAAR1HTR2ADPP4F2SCN4A | |
| Hydrochloric Acid SCHEMBL18547879 | 0.97 | TAAR1 (0.59) | TAAR1HTR2ADPP4F2SCN4A | |
| Hydrochloric Acid SCHEMBL28583636 | 0.97 | TAAR1 (0.59) | TAAR1HTR2ADPP4F2SCN4A | |
| Hydrochloric Acid SCHEMBL6694632 | 0.97 | TAAR1 (0.59) | TAAR1HTR2ADPP4F2SCN4A | |
| Hydrochloric Acid SCHEMBL4696174 | 0.97 | TAAR1 (0.59) | TAAR1HTR2ADPP4F2SCN4A | |
| SCHEMBL15558709 | 0.89 | TAAR1 (0.50) | TAAR1HTR2ADPP4F2SCN4A | |
| SCHEMBL6742097 | 0.89 | TAAR1 (0.50) | TAAR1HTR2ADPP4F2SCN4A | |
| Toluene SCHEMBL28855142 | 0.89 | TAAR1 (0.50) | TAAR1HTR2ASCN4A | |
| Acetic Acid SCHEMBL2393284 | 0.87 | GABBR2 (0.50) | TAAR1HTR2ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2679588-B1 | ASYMMETRIC SYNTHESIS METHOD, RELATED RAW MATERIAL AND PREPARATION METHOD OF (S,S)-2,8-DIAZABICYCLO[4,3,0]NONANE | SHANGHAI PUYI CHEMICAL TECHNOLOGY CO LTD (CN) | 2015-07-08 | — | — | EP | claimed |
| US-20140066626-A1 | ASYMMETRIC SYNTHESIS METHOD, RELATED RAW MATERIAL AND PREPARATION METHOD OF (S,S)-2,8-DIAZABICYCLO[4,3,0]NONANE | Shanghai Puyi Chemical Technology Co. Ltd (CN) | 2014-03-06 | — | — | US | claimed |
| US-20220370453-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY | STORM THERAPEUTICS LIMITED (GB) | 2022-11-24 | — | — | US | disclosed |
| CN-111748000-B | 3-deoxy-5-hydroxy-1-amino carbo-carbohydrate compounds and uses thereof | 沈阳药科大学 | 2022-05-20 | — | — | CN | disclosed |
| EP-3986568-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY | Storm Therapeutics Ltd (GB) | 2022-04-27 | — | — | EP | disclosed |
| CN-114286711-A | Bicyclic heterocyclic compounds as inhibitors of BCDIN3D activity | 风暴治疗有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-20220033397-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-02-03 | — | — | US | disclosed |
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113365696-A | Pharmaceutical compounds and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-111748000-A | 3-deoxy-5-hydroxy-1-amino carbo-carbohydrate compounds and uses thereof | 沈阳药科大学 | 2020-10-09 | — | — | CN | disclosed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| EP-0741731-A1 | PROCESS FOR EPOXIDISING PROCHIRAL OLEFINS AND A CATALYST THEREFOR AND INTERMEDIATES FOR MAKING THE CATALYST | SMITHKLINE BEECHAM PLC (GB) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995021172-A1 | PROCESS FOR EPOXIDISING PROCHIRAL OLEFINS AND A CATALYST THEREFOR AND INTERMEDIATES FOR MAKING THE CATALYST | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-08-10 | — | — | WO | disclosed |
| EP-0384364-B1 | A composition of nonlinear optical materials and a method for preparing the same | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 1994-01-19 | — | — | EP | disclosed |
| EP-0431991-B1 | 1,8-Benzonaphthyridine derivatives, their preparation and compositions containing them | BELLON LABOR SA ROGER (FR) | 1994-01-12 | — | — | EP | disclosed |
| US-5053509-A | Microbiocides; AIDS | LABORATOIRE ROGER BELLON (FR) | 1991-10-01 | — | — | US | disclosed |
| EP-0431991-A1 | 1,8-Benzonaphthyridine derivatives, their preparation and compositions containing them | Société anonyme dite: LABORATOIRE ROGER BELLON (FR) | 1991-06-12 | — | — | EP | disclosed |
| US-5009815-A | Composition of nonlinear optical materials and a method for preparing the same | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1991-04-23 | — | — | US | disclosed |
| EP-0384364-A2 | A composition of nonlinear optical materials and a method for preparing the same | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1990-08-29 | — | — | EP | disclosed |
| US-4463173-A | ANTIBIOTIC, BACTERICIDE | ICI PHARMA (FR) | 1984-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033397-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | USP19, USP16, USP18 | TAAR1 4648/4885HTR2A 4195/4885DPP4 51/4885 |
| US-20140066626-A1 | ASYMMETRIC SYNTHESIS METHOD, RELATED RAW MATERIAL AND PREPARATION METHOD OF (S,S)-2,8-DIAZABICYCLO[4,3,0]NONANE | SULT1E1, SULT1A1, PYM1 | TAAR1 2462/4885HTR2A 3524/4885DPP4 1776/4885 |
| US-20220370453-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY | BCDIN3D, CDK3, CCNI | TAAR1 4761/4885HTR2A 3974/4885DPP4 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.